Table 3.
Criteria | Ho et al. [20] | Casapao et al. [21] | Vazquez et al. [22] | Lin et al. [23] | Polenakovitch et al. [24] | Sakoulas et al. [25] | Santos et al. [26] |
---|---|---|---|---|---|---|---|
Total number of patients who received ceftaroline, n | 6 | 630 | 48 (27 with ABSSSI and 21 with CABP) | 10 | 31 | 26 | 647 |
Patients with MRSA, n (%) | 6 (100%) | 241 (38%) | 16 (59%) with ABSSSI and 16 (76%) with CABP | 10 (100%) | 31 (100%) | 20 (76%) | 191 (29%) |
Patients who received antibiotics prior to ceftaroline | 6 | 422 | 14 with ABSSSI and 13 with SAB | 10 | 31 | 26 | 515 |
Duration of treatment with ceftaroline, median (range) | Varies per case | 6 days | 5.8 days for ABSSSI and 7 days for CABP | Varies per case | 5 days | 16 days | 6 days |
Number of patients that were treated with ceftaroline as monotherapy | 6 | 447 | 22 in ABSSSI and 10 in CABP | - | - | none | 114 |
Clinical success of MRSA patients, n (%) | 5 (83%) | 426/484 (88%) | 8/16 (50%) with ABSSSI And 10/16 (63%) with CABP |
6 (60%) | 23 (74%) | 23 (88%) | 144/178 (81%) |
Safety outcome | GI bleeding and death reported in one patient | 8% hospital mortality 0.9% diarrhea 0.6% vomiting 1.1% renal failure |
- | Rash, eosinophilia, pruritis and clostridium difficile infection | Eosinophilic pneumonia, rash and diarrhea | - | - |